'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.
'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.
复制标题
DOI：
10.1016/j.ddtec.2004.10.002
复制
发表时间：
2004-12-01
期刊：
影响因子：
--
通讯作者：
Tucker, Geoff
中科院分区：
文献类型：
--
作者：
Rostami-Hodjegan, Amin;Tucker, Geoff
最近，代谢药物相互作用（M-DDI）在药物开发中引起了一些备受关注的问题，导致监管机构限制使用，撤回或不予批准。使用体外技术评价M-DDI的潜力已成为药物开发过程中的常规方法。然而，由于缺乏综合办法，它们的解释和价值仍然是辩论的主题，有用的“模拟”和精确的“预测”之间的重要区别往往没有得到重视。各种计算机软件现在可用于模拟M-DDI。然而，业界必须作出协调一致的努力，以评估其使用情况。FDA最近强调了这种合作对改善新药开发关键途径的重要性。M-DDI的计算机模拟有可能为该过程增加重要价值。
Recently, metabolic drug-drug interactions (M-DDI) have raised some high-profile problems in drug development resulting in restricted use, withdrawal or non-approval by regulatory agencies. The use of in vitro technologies to evaluate the potential for M-DDI has become routine in the drug development process. Nevertheless, in the absence of an integrated approach, their interpretation and value remains the subject of debate, and the vital distinction between a useful "simulation" and a precise "prediction" is not often appreciated. Various in silico softwares are now available for the simulation of M-DDI. However, a concerted effort by the industry is necessary to evaluate their use. The FDA has recently emphasised the importance of such collaboration to improve the crucial path to development of new drugs. In silico simulation of M-DDI has the potential to add significant value to this process.: